Stocks open lower as White House restricts semiconductor exports, earnings season rolls on
Stocks open lower as White House restricts semiconductor exports, earnings season rolls on
Show Caption
Hide Caption
Senator Van Hollen travels to El Salvador for Abrego Garcia
"We are going to keep fighting." Senator Van Hollen of Maryland left for El Salvador to push for Kilmar Abrego Garcia's release.
Stocks fell after the opening bell Wednesday as investors grappled with another twist in the ongoing U.S. trade war.
The Dow 30 Industrials shed 156 points, 0.4%, to open near 40,369, while the broad S&P 500 was off 0.2%, or 9 points, near 5,397. The tech-heavy Nasdaq Composite Index was little changed, near 16,823.
Shares of behemoth chipmaker Nvidia tumbled nearly 6%. The company on Tuesday night announced that the U.S. government was limiting exports of one of its chips to China.
The 10-year U.S. Treasury note was little changed at 4.32%, down more than 20 basis points from its level last week, when a sharp sell-off rattled markets. Bond yields rise as prices fall, and vice versa. Gold tacked on another 2.5% to push above $3,300. The precious metal is now up more than 27% in the year so far.
Corporate news
Shares of Abbott Labs gained 4.5% after the healthcare products company reported results before the bell. Earnings slightly topped analyst expectations, but revenue missed.
Semiconductor stocks sank: the iShares Semiconductor ETF, which tracks those stocks, was off nearly 4%.
Economic news
More: Imports to US remained at near record levels in February as tariff fears persisted
Industrial production, or manufacturing and mining activity, rose by 0.7% in February 2025, the third consecutive month of increases and topping analyst expectations of a 0.2% rise.
Retail sales rose 1.4% in March, the strongest monthly gain since January 2023, the government said, as shoppers hurried to get ahead of fresh tariff announcements.
Federal Reserve Chair Jerome Powell is due to talk about the economic outlook in the afternoon.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Upturn
an hour ago
- Business Upturn
CORRECTION — Payden & Rygel
LOS ANGELES, June 09, 2025 (GLOBE NEWSWIRE) — In a release issued earlier today by Payden & Rygel, please note we have corrected the proper name of the Payden & Rygel municipal bond team in the headline, as well as the first and second paragraphs. The corrected release follows: Default ahead for California? Unlikely, says New Report From Payden & Rygel's California Municipal Bond Team Recent concerns over California's fiscal health—driven by declining initial public offering (IPO) volume, reduced federal funding risk, and rising costs—have prompted questions about the state's financial stability. However, after a thorough analysis, Payden & Rygel's municipal bond team believes the risk of a bond default or severe credit deterioration remains low. 'While we understand investors' concerns about the California economy, its capacity to generate adequate revenue to match spending levels and the potential impact on the state's municipal debt, we believe that although the revenue picture is softening, the outlook remains relatively stable over the next 1-2 years with potential credit rating deterioration limited to just one notch over that timeframe in a worst case scenario. Near term ratings will hinge on the final FY 26 budget that we expect Sacramento to pass by June 15th, otherwise lawmakers don't get paid,' say the report's authors, the Payden & Rygel's municipal bond team. 'We are also closely monitoring the evolution of entitlement spending reduction proposals at the federal level but ultimately expect Medicaid cuts to be less pervasive than currently feared,' they added. Here are six reasons to be optimistic: Reason 1: Legal structure. The 10th amendment prohibits states, including California, from filing for bankruptcy. While defaults are technically possible, California is nowhere near default based on current indicators. Reason 2: Strong revenues, limited impact from IPO weakness With less than a month in the current fiscal year, tax revenues are weakening but remain strong, with Governor Newsom's recent May Revision projecting a relatively small $12 billion projected for next year. IPO activity, while down, is not a core revenue driver. Its recent decline reflects a normalization post-COVID stimulus, not a structural weakness. Reason 3: Credit ratings are stable All three major credit agencies S&P, Moody's, and Fitch—rate California AA-/Aa2/AA, respectively, all with stable outlooks but we expect the ratings agencies to refine their views this summer following the finalization of the FY 2026 budget process by the end of June. Reason 4: A strong economy with healthy reserves California's gross domestic product (GDP) ranks #4 globally, recently surpassing Japan, underscoring a broad, diverse and innovative state economy with a deep employment base. Although reserves have dipped since 2023 due to pandemic fund drawdowns and budgetary uncertainty in FY 2023/2024 due to delayed tax receipts, they remain at comparatively strong levels historically that will grant state leadership time to navigate federal policy uncertainty, which Governor Newsom blames for a softening of revenue. Reason 5: Manageable liabilities Debt service is low at 3–4% of governmental expenditures, and pension funding remains solid. Because of constitutional protections that prioritize education and debt payments, revenue would need to drop over 50% to threaten debt service. For context, State revenues dropped 15% in 2008. Reason 6: Credit conditions are weakening but remain healthy Despite uncertainty, California retains healthy credit fundamentals with relatively stable ratings, manageable deficits, excellent access to liquidity and conservative budgeting assumptions that support bondholder confidence. In summary, while recent headlines surrounding tariffs, fiscal tightening, and economic uncertainty have contributed to heightened market anxiety, our base case remains firm: Although California's credit profile is softening, it continues to demonstrate resilience, supported by a vast and diversified tax base, substantial reserve levels across all governmental funds, and long-term liabilities that we consider both moderate and manageable. Here is a link to the full report. ABOUT PAYDEN & RYGEL With $165 billion under management, Payden & Rygel is one of the largest privately-owned global investment advisers focused on the active management of fixed income and equity portfolios. Payden & Rygel provides a full range of investment strategies and solutions to investors around the globe, including Central Banks, Pension Funds, Insurance Companies, Private Banks, and Foundations. Independent and privately-owned, Payden is headquartered in Los Angeles and has offices in Boston, London, and Milan. Visit for more information about Payden's investment offerings, including US mutual funds and Irish-domiciled funds (subject to investor eligibility). This material reflects the firm's current opinion and is subject to change without notice. Sources for the material contained herein are deemed reliable but cannot be guaranteed. This material is for illustrative purposes only and does not constitute investment advice or an offer to sell or buy any security. Past performance is no guarantee of future results. For press requests, please contact:Kate Ennis [email protected] 301-580-6726
Yahoo
an hour ago
- Yahoo
FedEx (FDX) Exceeds Market Returns: Some Facts to Consider
FedEx (FDX) ended the recent trading session at $222.18, demonstrating a +1.17% swing from the preceding day's closing price. The stock's performance was ahead of the S&P 500's daily gain of 0.09%. The the stock of package delivery company has risen by 0.82% in the past month, lagging the Transportation sector's gain of 7.55% and the S&P 500's gain of 7.21%. The investment community will be closely monitoring the performance of FedEx in its forthcoming earnings report. The company is scheduled to release its earnings on June 24, 2025. The company is expected to report EPS of $6, up 10.91% from the prior-year quarter. Alongside, our most recent consensus estimate is anticipating revenue of $21.68 billion, indicating a 1.96% downward movement from the same quarter last year. Investors should also note any recent changes to analyst estimates for FedEx. These recent revisions tend to reflect the evolving nature of short-term business trends. Therefore, positive revisions in estimates convey analysts' confidence in the company's business performance and profit potential. Empirical research indicates that these revisions in estimates have a direct correlation with impending stock price performance. To utilize this, we have created the Zacks Rank, a proprietary model that integrates these estimate changes and provides a functional rating system. The Zacks Rank system, running from #1 (Strong Buy) to #5 (Strong Sell), holds an admirable track record of superior performance, independently audited, with #1 stocks contributing an average annual return of +25% since 1988. Over the last 30 days, the Zacks Consensus EPS estimate has witnessed a 0.07% decrease. As of now, FedEx holds a Zacks Rank of #3 (Hold). In the context of valuation, FedEx is at present trading with a Forward P/E ratio of 11.11. This signifies a discount in comparison to the average Forward P/E of 13.87 for its industry. We can also see that FDX currently has a PEG ratio of 1.04. The PEG ratio is akin to the commonly utilized P/E ratio, but this measure also incorporates the company's anticipated earnings growth rate. FDX's industry had an average PEG ratio of 1.72 as of yesterday's close. The Transportation - Air Freight and Cargo industry is part of the Transportation sector. This industry, currently bearing a Zacks Industry Rank of 90, finds itself in the top 37% echelons of all 250+ industries. The Zacks Industry Rank gauges the strength of our industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1. Keep in mind to rely on to watch all these stock-impacting metrics, and more, in the succeeding trading sessions. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report FedEx Corporation (FDX) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
an hour ago
- Yahoo
Bristol Myers Squibb (BMY) Exceeds Market Returns: Some Facts to Consider
In the latest trading session, Bristol Myers Squibb (BMY) closed at $49, marking a +1.22% move from the previous day. The stock's performance was ahead of the S&P 500's daily gain of 0.09%. The the stock of biopharmaceutical company has risen by 4.22% in the past month, leading the Medical sector's gain of 2.17% and undershooting the S&P 500's gain of 7.21%. Market participants will be closely following the financial results of Bristol Myers Squibb in its upcoming release. The company is predicted to post an EPS of $1.67, indicating a 19.32% decline compared to the equivalent quarter last year. At the same time, our most recent consensus estimate is projecting a revenue of $11.32 billion, reflecting a 7.19% fall from the equivalent quarter last year. For the annual period, the Zacks Consensus Estimates anticipate earnings of $6.85 per share and a revenue of $46.31 billion, signifying shifts of +495.65% and -4.11%, respectively, from the last year. Additionally, investors should keep an eye on any recent revisions to analyst forecasts for Bristol Myers Squibb. These latest adjustments often mirror the shifting dynamics of short-term business patterns. With this in mind, we can consider positive estimate revisions a sign of optimism about the company's business outlook. Research indicates that these estimate revisions are directly correlated with near-term share price momentum. Investors can capitalize on this by using the Zacks Rank. This model considers these estimate changes and provides a simple, actionable rating system. The Zacks Rank system, which varies between #1 (Strong Buy) and #5 (Strong Sell), carries an impressive track record of exceeding expectations, confirmed by external audits, with stocks at #1 delivering an average annual return of +25% since 1988. Over the past month, there's been a 0.57% fall in the Zacks Consensus EPS estimate. Right now, Bristol Myers Squibb possesses a Zacks Rank of #3 (Hold). Looking at valuation, Bristol Myers Squibb is presently trading at a Forward P/E ratio of 7.06. Its industry sports an average Forward P/E of 19.71, so one might conclude that Bristol Myers Squibb is trading at a discount comparatively. It is also worth noting that BMY currently has a PEG ratio of 1.41. The PEG ratio bears resemblance to the frequently used P/E ratio, but this parameter also includes the company's expected earnings growth trajectory. BMY's industry had an average PEG ratio of 1.43 as of yesterday's close. The Medical - Biomedical and Genetics industry is part of the Medical sector. At present, this industry carries a Zacks Industry Rank of 78, placing it within the top 32% of over 250 industries. The Zacks Industry Rank gauges the strength of our industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1. Remember to apply to follow these and more stock-moving metrics during the upcoming trading sessions. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Bristol Myers Squibb Company (BMY) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
